Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma

  • Scott R. Plotkin
  • , Dan G. Duda
  • , Alona Muzikansky
  • , Jeffrey Allen
  • , Jaishri Blakeley
  • , Tena Rosser
  • , Jian L. Campian
  • , D. Wade Clapp
  • , Michael J. Fisher
  • , James Tonsgard
  • , Nicole Ullrich
  • , Coretta Thomas
  • , Gary Cutter
  • , Bruce Korf
  • , Roger Packer
  • , Matthias A. Karajannis

Research output: Contribution to journal › Article › peer-review

101 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience